Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease
In this medfyle
This study investigated whether SGLT2i can safely and effectively improve cardiovascular and renal outcomes in patients with T2D and advanced CKD. In patients with CKD treated with an SGLT2i, continuation of an SGLT2i after eGFR declined to ≤30 ml/min/1.73 m2 was associated with lower risks of cardiovascular and renal events vs. discontinuation of the SGLT2i.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article: Lin DS, Lee JK, Huang KC, Lin TT, Lo HY. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia. 2024 Nov;67(11):2459-2470.
The authors of the original article had no part in the creation of the summary.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Diabetologia, by agreement with Springer.
